Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Cancer treatment breakthroughs stories

Nov 16, 2026

CG Oncology bladder cancer immunotherapy cuts tumor recurrence risk by 68% in Phase 3

CG Oncology reported its oncolytic immunotherapy met the primary endpoint of a late-stage trial in non-muscle invasive bladder cancer, reducing tumor recurrence risk by 68%.

Nov 16, 2026·3 sources
00
Nov 13, 2026

FDA approves durvalumab plus enfortumab vedotin for muscle-invasive bladder cancer

The FDA approved AstraZeneca's durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for muscle-invasive bladder cancer. The approval adds a new perioperative immunotherapy option for this high-risk cancer.

Nov 13, 2026·2 sources
00
Oct 29, 2026

METTL13 enzyme found to fuel cancer growth by boosting KRAS protein production

Researchers at MD Anderson Cancer Center discovered that the METTL13 enzyme modifies translation machinery to selectively enhance production of cancer-driving proteins like KRAS, offering a potential new therapeutic target upstream of existing KRAS-targeted drugs that face resistance issues.

Oct 29, 2026·3 sources
00

Roswell Park researchers identify timing window for immunotherapy in prostate cancer treatment

Researchers at Roswell Park Comprehensive Cancer Center have discovered that hormone-blocking therapies commonly used to treat prostate cancer temporarily activate the body's immune response, revealing a critical window for boosting immunotherapy effectiveness.

Oct 29, 2026·1 source
00
Oct 27, 2026

BYU researchers develop MOTO-CAR macrophage therapy to target solid tumors in preclinical study

Preclinical research demonstrates that macrophages can be programmed to fight solid cancer tumors, offering a potential new immunotherapy approach. The development comes as cancer kills one person every 50 seconds in the U.S., with some cancers continuing to resist current treatments.

Oct 27, 2026·2 sources
00
Oct 26, 2026

Merck drug extends survival in endometrial cancer, wins FDA priority review

Merck's experimental antibody-drug conjugate reduced death risk by one-third in advanced endometrial cancer patients and received FDA priority review based on late-stage trial data.

Oct 26, 2026·3 sources
00

Genmab's ovarian cancer drug cuts death risk 57% in late-stage trial

Genmab's experimental antibody-drug conjugate Rina-S reduced the risk of death by 57% compared to chemotherapy in patients with advanced ovarian cancer, according to phase 3 trial results presented at ESMO. The Danish drugmaker's shares surged over 12% on the news.

Oct 26, 2026·2 sources
00
Oct 25, 2026

Roche's divarasib cuts death risk 44% in lung cancer trial vs Amgen, Bristol Myers drugs

Roche's next-generation KRAS G12C inhibitor divarasib reduced the risk of death by 44% compared to current treatments in previously treated mutant non-small cell lung cancer patients, with median overall survival reaching nearly 6 months longer than competitors.

Oct 25, 2026·4 sources
00

AstraZeneca's sone-ve extends overall survival in advanced stomach cancer trial

AstraZeneca's experimental antibody-drug conjugate sone-ve doubled survival time in patients with advanced stomach cancer who had received at least two prior treatments, exceeding analyst expectations in late-stage trial data.

Oct 25, 2026·2 sources
00
Oct 24, 2026

Amgen's Imdelltra combo cuts death risk 58% in small cell lung cancer trial

Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced the risk of death by 58% compared to Imfinzi alone in patients with extensive-stage small cell lung cancer, adding eight months of life in a late-stage trial presented at ESMO.

Oct 24, 2026·3 sources
00

Nearly 30% of advanced melanoma patients achieve complete tumor disappearance with lifileucel TIL therapy plus pembrolizumab

Clinical trial results show 29.2% of patients with advanced melanoma experienced complete tumor disappearance on scans after receiving lifileucel TIL therapy combined with pembrolizumab immune checkpoint inhibitor as first-line treatment. The IOV-COM-202 trial demonstrates significant efficacy for this combination immunotherapy approach.

Oct 24, 2026·1 source
00
Oct 23, 2026

Bristol Myers Squibb and SystImmune breast cancer drug reduces disease progression risk by 59% in phase 3 trial

Bristol Myers Squibb and partner SystImmune announced that their experimental breast cancer treatment izalontamab brengitecan reduced the risk of disease progression or death by 59% compared to standard chemotherapy in patients with advanced HR+/HER2- breast cancer in the phase 3 PANKU-Breast01 study. The late-breaking results are being presented at ESMO 2026.

Oct 23, 2026·4 sources
00

Novartis breast cancer drug Kisqali cuts death risk by 19% after six years in early-stage trial

Novartis reported that its drug Kisqali helped extend survival for women with high-risk, early-stage breast cancer, cutting their risk of death by 19% after six years in trial data.

Oct 23, 2026·2 sources
00

Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Tango Therapeutics reported an 82% tumor response rate in a clinical trial combining targeted drugs for advanced pancreatic cancer, presented at ESMO congress.

Oct 23, 2026·2 sources
00

Johnson & Johnson prostate cancer drug JNJ-6143 shows tumor shrinkage in early-stage trial

Johnson & Johnson reported promising results from an early-stage clinical trial of its experimental oral prostate cancer treatment JNJ-6143, with 77% of patients with advanced prostate cancer experiencing significant drops in PSA levels after treatment. The trial involved patients who had undergone multiple prior treatments.

Oct 23, 2026·4 sources
00

New analysis shows daraxonrasib survival benefits across patient groups in advanced pancreatic cancer

A new analysis of a phase 3 clinical trial presented at ESMO 2026 found that daraxonrasib, a recently approved targeted therapy, improved survival compared with standard chemotherapy across multiple patient groups with advanced pancreatic cancer. The drug represents the biggest advance in decades against the notoriously hard-to-treat disease.

Oct 23, 2026·4 sources
00
Oct 22, 2026

Moderna and Merck melanoma vaccine cuts death or recurrence risk by 42% in phase 3 trial

The mRNA-based personalized cancer vaccine combined with Keytruda reduced the risk of melanoma death or recurrence by 42% in a late-stage trial, though leaked data triggered a sell-off in Moderna shares despite meeting expectations.

Oct 22, 2026·5 sources
00
Oct 19, 2026

Disc Medicine's erythropoietic protoporphyria drug succeeds in late-stage trial

Disc Medicine's experimental pill for erythropoietic protoporphyria, a rare disease causing extreme pain from sunlight, met all primary and secondary goals in a late-stage trial, sending shares surging.

Oct 19, 2026·2 sources
00

Roche partners with Hansoh Pharma in deal worth over $15 billion

Roche has entered a partnership and licensing deal with China's Hansoh Pharmaceutical worth potentially more than $15 billion, covering a portfolio of antibody-drug conjugates across multiple cancer types.

Oct 19, 2026·3 sources
00
Oct 18, 2026

India cuts prices of 137 cancer drugs by up to 70% under expanded price controls

India's Ministry of Chemicals and Fertilizers announced it will reduce prices of 137 cancer medicines by up to 70% through widened price controls, aiming to make treatment more affordable for patients.

Oct 18, 2026·2 sources
00
Oct 17, 2026

Pope Leo XIV discharged after lung cancer surgery

Pope Leo XIV was discharged from Rome's Gemelli Hospital four days after surgery to remove a cancerous nodule from his lungs. The Vatican said blood tests and imaging cleared him for discharge, with rigorous travel scheduled ahead.

Oct 17, 2026·6 sources
00
Oct 15, 2026

Revolution Medicines wins EU panel backing for pancreatic cancer drug Rasonque

The European Medicines Agency's advisory committee recommended approval of Revolution Medicines' Rasonque for adults with metastatic pancreatic cancer that has progressed after at least one prior therapy.

Oct 15, 2026·2 sources
00

Iambic Therapeutics raises $150M in IPO for AI-driven cancer pipeline

Nvidia-backed Iambic Therapeutics completed a $150 million IPO at $16 per share to advance its AI-designed cancer drugs and platform partnerships with major pharma companies.

Oct 15, 2026·2 sources
00
Oct 14, 2026

FDA expands Anktiva approval for bladder cancer treatment

The FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer, expanding the drug's approved indications.

Oct 14, 2026·2 sources
00

Verastem raises $250M as KRAS inhibitor shows promise in pancreatic cancer

Verastem Oncology announced encouraging early results for its KRAS G12D inhibitor in pancreatic cancer patients alongside a $250 million fundraise and CEO departure, positioning itself as a competitor to Revolution Medicines in next-generation KRAS treatments.

Oct 14, 2026·3 sources
00

Vir Biotechnology and Gilead partner on $1.88B cancer therapy deal

Vir Biotechnology signed a collaboration agreement worth up to $1.88 billion with Gilead Sciences to discover and develop T cell engager treatments for solid tumors, with Gilead paying $65 million upfront and $45 million in near-term milestones.

Oct 14, 2026·2 sources
00
Oct 13, 2026

BioNTech's mRNA cancer therapy fails primary endpoint in head and neck trial

BioNTech announced its investigational mRNA cancer treatment did not meet the primary endpoint in a late-stage trial for head and neck cancer, marking a setback for the company's oncology pipeline.

Oct 13, 2026·2 sources
00

Pope Leo XIV diagnosed with lung cancer after surgery removes lower lobe

The Vatican announced Pope Leo XIV has been diagnosed with lung cancer following a successful 90-minute surgery that removed the lower lobe of his right lung. The 71-year-old American pontiff faces a week of recovery.

Oct 13, 2026·7 sources
00
Oct 12, 2026

Bristol Myers experimental drugs show promise in late-stage lung disease and cancer trials

Bristol Myers Squibb reported positive results from late-stage trials of experimental drugs for treating a rare endocrine cancer and idiopathic pulmonary fibrosis, with the radiopharmaceutical therapy significantly delaying disease progression in gastrointestinal and pancreatic tumors.

Oct 12, 2026·3 sources
00
Oct 9, 2026

FDA approves atezolizumab with chemotherapy for stage III colon cancer

The FDA has approved atezolizumab (Tecentriq) in combination with chemotherapy as adjuvant treatment for adult and pediatric patients aged 2 years or older with stage III mismatch repair-deficient colon cancer.

Oct 9, 2026·2 sources
00
Oct 8, 2026

Endeavor BioMedicines' IPF drug meets Phase 2b primary endpoint

Endeavor BioMedicines announced that taladegib met the primary endpoint in a Phase 2b study for idiopathic pulmonary fibrosis, with the company claiming the drug has potential to reverse disease course rather than just slow progression.

Oct 8, 2026·2 sources
00
Oct 7, 2026

Merck blocked from selling injectable Keytruda in Europe after patent ruling

A Dutch patent court ruled in favor of Halozyme against Merck, ordering the drugmaker to halt manufacture and sale of injectable Keytruda in eight European countries due to patent infringement.

Oct 7, 2026·2 sources
00
Oct 5, 2026

AbbVie and Genmab's Epkinly succeeds in first-line lymphoma trial

AbbVie and Genmab reported that their T-cell engager Epkinly met primary endpoints in a Phase 3 trial for first-line diffuse large B-cell lymphoma, reducing risk of disease progression or death by 51%.

Oct 5, 2026·3 sources
00

FDA approves Lilly's Jaypirca as first-line CLL therapy

The FDA approved pirtobrutinib (Jaypirca, Eli Lilly) for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion.

Oct 5, 2026·2 sources
00

GE HealthCare to acquire Sofie Biosciences for $945 million

GE HealthCare will buy privately held Sofie Biosciences for $945 million in cash to strengthen its radiopharmaceutical manufacturing and PET imaging capabilities.

Oct 5, 2026·2 sources
00
Oct 2, 2026

Pirtobrutinib wins FDA approval for frontline CLL/SLL treatment

The FDA expanded approval of pirtobrutinib, a non-covalent BTK inhibitor, for chronic lymphocytic leukemia and small lymphocytic lymphoma in the frontline setting.

Oct 2, 2026·2 sources
00
Sep 28, 2026

AstraZeneca invests $2 billion in Summit Therapeutics for cancer drug collaboration

AstraZeneca is investing $2 billion in Summit Therapeutics and collaborating on clinical trials testing their cancer treatments together, with AstraZeneca taking an equity stake in the biotech company.

Sep 28, 2026·5 sources
00

Merck licenses KRAS G12D cancer drug from SciBrunch for $400 million upfront

Merck agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug targeting the KRAS G12D mutation, continuing a trend of U.S. drugmakers licensing China-developed therapies.

Sep 28, 2026·3 sources
00

Merck and Daiichi abandon accelerated approval plans for lung cancer ADC

Merck and Daiichi Sankyo ended plans to seek accelerated FDA approval for their antibody-drug conjugate I-DXd in lung cancer after the agency indicated existing data wouldn't support the pathway, erasing a competitive advantage over rivals.

Sep 28, 2026·2 sources
00
Sep 21, 2026

Grail's multi-cancer blood test shows no major safety concerns in FDA review

FDA staff reviewers found no major concerns about the accuracy and safety of Grail's blood test designed to detect more than 50 cancers ahead of an advisory committee meeting. The company's shares surged 35% on the news.

Sep 21, 2026·3 sources
00

Ivonescimab extends survival vs pembrolizumab in PD-L1+ advanced NSCLC trial

First-line ivonescimab significantly prolonged overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer, according to updated analysis from a clinical trial.

Sep 21, 2026·2 sources
00
Sep 17, 2026

CVS Aetna streamlines cancer prior authorizations into single unified request

CVS Health's Aetna insurance division is combining all different preapproval requirements for cancer care into one unified request starting next year, simplifying the authorization process for cancer patients.

Sep 17, 2026·3 sources
00
Aug 19, 2026

Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence in late-stage trial

Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.

Aug 19, 2026·6 sources
00
Aug 14, 2026

FDA approves Bristol Myers Squibb's Zenbexus, first CELMoD drug for multiple myeloma

The FDA has approved Zenbexus (iberdomide) for multiple myeloma treatment, marking the first approval in the novel CELMoD drug class that uses targeted protein degradation. Bristol Myers Squibb acquired the therapy through its Celgene acquisition and is positioning it as a successor to its legacy myeloma products.

Aug 14, 2026·4 sources
00
Aug 13, 2026

Taiho and Cullinan's zipalertinib succeeds in phase 3 lung cancer trial

Taiho Oncology and Cullinan Therapeutics announced their next-generation EGFR inhibitor zipalertinib significantly improved progression-free survival in a registrational phase 3 trial for first-line treatment of advanced non-small cell lung cancer. The results position the drug as a competitor to multiple approved medicines in the EGFR-mutated lung cancer market.

Aug 13, 2026·4 sources
00
Aug 6, 2026

FDA approves Replimune's melanoma drug after two prior rejections

The FDA granted accelerated approval to Replimune's TUDRIQEVTM (vusolimogene oderparepvec-wtpg) for melanoma treatment, reversing two earlier rejections following support from an advisory panel. The approval marks a significant turnaround for the biotech company after a tumultuous regulatory process.

Aug 6, 2026·3 sources
00
Aug 2, 2026

FDA expands Pluvicto approval for earlier-stage metastatic prostate cancer treatment

The FDA has approved Novartis' radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for use in combination with hormone therapy for patients with PSMA-positive metastatic prostate cancer who are still hormone-sensitive, nearly doubling the eligible patient population from its previous indication for hormone-resistant cases.

Aug 2, 2026·8 sources
00
Jul 31, 2026

FDA Advisory Committee Votes 10-3 in Favor of Replimune's RP1 Efficacy Data from Ignyte Study

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee determined that efficacy data from Replimune's Ignyte study for RP1 is evaluable and clinically meaningful, voting 10 to 3 in favor.

Jul 31, 2026·1 source
00
Jul 28, 2026

GSK partner Hansoh Pharmaceutical's bone cancer drug meets primary endpoint in second Phase III trial in China

Hansoh Pharmaceutical announced positive results from the ARTEMIS-011 Phase III trial in China, with its experimental drug Ris-Rez meeting the primary endpoint of progression-free survival in relapsed bone cancer patients. This marks the second Phase III success for the drug, strengthening GSK's oncology portfolio through its licensing partnership with the Chinese biotech.

Jul 28, 2026·3 sources
00
Jul 27, 2026

AstraZeneca's Sonesitatug Vedotin Shows Significant Survival Improvement in Phase III Gastric Cancer Trial

Phase III CLARITY-Gastric01 trial results showed sonesitatug vedotin (Sone-Ve) achieved statistically significant overall survival improvement in CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma patients in second-line and later settings, meeting its dual primary and key secondary endpoints.

Jul 27, 2026·4 sources
00
Jul 14, 2026

FDA Approves Celcuity's Revtorpyk (Gedatolisib) for Advanced Breast Cancer

The U.S. Food and Drug Administration has approved Revtorpyk (gedatolisib), Celcuity's first drug to reach market, for treating hormone receptor positive, HER2 negative advanced breast cancer. The approval sent the company's shares up 7% in extended trading.

Jul 14, 2026·4 sources
00
Jul 9, 2026

FDA Approves First Wearable On-Body Injector for Cancer Drug Delivery with Sanofi's Sarclisa

The FDA has approved Sanofi's Sarclisa (isatuximab) for subcutaneous delivery via a wearable on-body injector, marking the first cancer drug to receive approval for this delivery method. The device offers multiple myeloma patients a less burdensome alternative to intravenous infusions.

Jul 9, 2026·6 sources
00
Jul 2, 2026

Roche's divarasib outperforms Amgen and Bristol Myers Squibb drugs in Phase 3 lung cancer trial

Roche announced positive results from a head-to-head Phase 3 trial showing its KRAS G12C inhibitor divarasib demonstrated superior efficacy compared to competing treatments from Amgen and Bristol Myers Squibb in patients with KRAS-driven lung cancer.

Jul 2, 2026·4 sources
00

FDA Expands Casgevy Gene Therapy Approval to Children as Young as Two with Sickle Cell Disease and Beta Thalassemia

The FDA has approved Vertex Pharmaceuticals' Casgevy (exagamglogene autotemcel) for patients aged two years and older with sickle cell disease and transfusion-dependent beta thalassemia, expanding from the previous minimum age of 12 years. The approval was granted under the agency's Commissioner's National Priority Voucher program.

Jul 2, 2026·3 sources
00
Jun 30, 2026

FDA Approves Orca Bio's TREGZI as First Precision-Engineered Cell Therapy for Blood Cancer Transplants

The U.S. FDA has approved Orca Bio's TREGZI, the first precision-engineered cell therapy for allogeneic transplants in adults with hematological malignancies, designed to reduce stem cell transplant complications.

Jun 30, 2026·7 sources
00
Jun 29, 2026

AbbVie and Genmab's Epkinly Combination Meets Primary Endpoint in Phase 3 Trial for Relapsed/Refractory DLBCL

The EPCORE DLBCL-4 Phase 3 trial showed that epcoritamab (Epkinly) combined with lenalidomide significantly improved progression-free survival compared to R-GemOx chemotherapy in adults with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy. The results bring the bispecific antibody closer to a potential label expansion.

Jun 29, 2026·6 sources
00
Jun 24, 2026

FDA approves Trodelvy for first-line triple-negative breast cancer

The FDA approved sacituzumab govitecan-hziy (Trodelvy) on June 24, 2026, for two indications in adults with triple-negative breast cancer: as monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of advanced disease, offering new options beyond standard chemotherapy.

Jun 24, 2026·3 sources
00
Jun 22, 2026

China Approves World's First CAR-T Therapy for Solid Tumors to Treat Advanced Gastric Cancer

China's National Medical Products Administration has approved satricabtagene autoleucel (Satri-cel, CT041, Kaileimei®), marking the first CAR-T cell therapy approved globally for treating solid tumors, specifically for CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma.

Jun 22, 2026·4 sources
00
Jun 12, 2026

FDA Approves Belzutifan Plus Pembrolizumab as Adjuvant Therapy for Clear Cell Renal Cell Carcinoma

The FDA has approved the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant treatment for patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy, based on data from the phase 3 LITESPARK-022 trial.

Jun 12, 2026·3 sources
00
Jun 1, 2026

Moderna's personalized mRNA melanoma vaccine cuts cancer recurrence risk by half in five-year trial results

New clinical trial results presented at the American Society of Clinical Oncology show that Moderna's experimental personalized mRNA vaccine, combined with immunotherapy, significantly reduced the risk of deadly melanoma returning after five years. The vaccine is custom-made for each patient based on their specific tumor.

Jun 1, 2026·4 sources
00
May 31, 2026

Akeso and Summit's Lung Cancer Drug Extends Survival by 34% in Late-Stage China Trial

Ivonescimab, an experimental drug combining two immunotherapy mechanisms, reduced the risk of death by 34% compared to standard immunotherapy in patients with advanced squamous non-small cell lung cancer in a closely watched Chinese trial. The drug helped patients live 15% longer than BeOne Medicines' Tevimbra.

May 31, 2026·3 sources
00

Johnson & Johnson's Prostate Cancer Drug Reduces Risk of Cancer Spread and Death in Late-Stage Study

J&J's Erleada used with hormone-blocking therapy six months before and after prostate surgery improved cancer elimination rates and reduced the risk of cancer spread and death in a late-stage trial for prostate cancer patients.

May 31, 2026·2 sources
00

Experimental drug daraxonrasib nearly doubles survival time for pancreatic cancer patients in clinical trial

Clinical trial results show that daraxonrasib, an experimental daily pill, nearly doubled overall survival rates for patients with advanced pancreatic cancer compared to traditional chemotherapy. Medical experts are calling the results a 'game changer' for treating one of the deadliest forms of cancer.

May 31, 2026·8 sources
00

Novartis Experimental Radiopharma Drug Shows Anti-Tumor Activity in Early Prostate Cancer Study

Novartis reported early data showing its experimental actinium-based radiopharma drug demonstrated anti-tumor activity against prostate cancer, including in patients previously treated with its older therapies.

May 31, 2026·1 source
00
May 30, 2026

Incyte Blood Cancer Drug Combo Reduces Disease Progression Risk in Aggressive Lymphoma

Incyte's Monjuvi as part of a multi-drug regimen for an aggressive form of non-Hodgkin lymphoma reduced the risk of disease progression, relapse or death, though with a high side-effect rate.

May 30, 2026·1 source
00

Radioactive Brain Implant Reduces Tumor Recurrence and Boosts Survival After Cancer Surgery

Scientists found that using a radioactive implant precisely where a brain tumor was removed cuts tumor recurrence and improves survival for patients with brain metastases.

May 30, 2026·1 source
00

DNA Test Could Allow Millions of Breast Cancer Patients to Safely Avoid Chemotherapy

Scientists have developed a DNA test that can distinguish between breast cancer patients who are likely to benefit from chemotherapy and those who can safely avoid it, potentially sparing millions from unnecessary treatment.

May 30, 2026·1 source
00

Top claims

  • ▪Approximately 75% of newly diagnosed bladder cancers are non-muscle-invasive, a form of the disease that can recur and potentially grow into the bladder muscle
  • ▪Following the announcement of positive Phase 3 trial results on November 16, 2026, CG Oncology shares rose more than 30% to $98 in premarket trading
  • ▪Standard monitoring for intermediate-risk non-muscle-invasive bladder cancer requires patient evaluations every three months, with repeat surgical procedures performed whenever the cancer recurs

People involved

Jia Guo

Subtopics

Cancer & Oncology39Drug Policy, Pricing & Approval33Clinical trials30Drug Approval and Clinical Trials30Cancer treatment22Oncology20Cancer Types13FDA drug approval12Cancer immunotherapy11Cancer Treatment & Therapies11Immunotherapy11Pharma9Clinical Trial Design & Evaluation8Drug development8Targeted cancer therapy8Cancer research7Clinical evaluation6Pharmaceutical Industry5Cancer3Clinical trial endpoints3MRNA vaccine technology3Personalized medicine3Precision medicine3Biomedical research2

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories